Doubt has been cast on the potential for using genetically modified animals as pharmaceutical factories.

It follows the announcement of a delay of at least two years in the testing of the drug that was aiming to be first “pharmed” product to market. Analysts said there were now serious questions being asked about the future viability of the sector.